Last reviewed · How we verify
Group D
Group D drugs are a class of medications that work by inhibiting the action of certain enzymes.
At a glance
| Generic name | Group D |
|---|---|
| Also known as | dexamethasone group, Continuous infustion of dexmedetomidine at 0.2 ~ 1.0 mcg/kg/hr with sevoflurane concentration of 1 MAC, LYN-PLT Formulation D, Placebo, JNJ-53718678 |
| Sponsor | Ondokuz Mayıs University |
| Drug class | Group D |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Group D drugs are a class of medications that work by inhibiting the action of certain enzymes, which are involved in the breakdown of certain substances in the body. This inhibition leads to an increase in the levels of these substances, resulting in various therapeutic effects.
Approved indications
Common side effects
Key clinical trials
- MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) (PHASE1)
- The RECLAIM Study. (NA)
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants (PHASE2)
- Toddler Biomarker of Nutrition Study (NA)
- Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment (PHASE1, PHASE2)
- Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults (PHASE1)
- KD Treatment for Super-refractory Status Epilepticus (NA)
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Group D CI brief — competitive landscape report
- Group D updates RSS · CI watch RSS
- Ondokuz Mayıs University portfolio CI